专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012075253A2 PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：药物组合物
公开(公告)号：WO2012075253A2
公开(公告)日：2012-06-07
申请号：PCT/US2011062837
申请日：2011-12-01
申请人： NOVARTIS AG , CAO YU , HACKL WOLFGANG , LI PING , LI SHOUFENG , MIRZA TAHSEEN , ZEHENDER HARTMUT , ZHU JIAHAO
发明人： CAO YU , HACKL WOLFGANG , LI PING , LI SHOUFENG , MIRZA TAHSEEN , ZEHENDER HARTMUT , ZHU JIAHAO
IPC分类号： A61K9/16 , A61P35/00
CPC分类号： C07D471/04 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1694 , A61K31/00
摘要： The present invention relates to a pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), which comprises granules that comprise at least therapeutic compound of formula (I) (see below), particularly 2-Methyl-2-[4-(3-methyl-2-oxo-8- quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile or 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition; and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing. The present invention also relates to processes for making such pharmaceutical compositions; a kit comprising such pharmaceutical composition and the instructions provide that the pharmaceutical composition may be taken immediately to about thirty minutes after the consumption of food; and related uses and methods of treatment.
摘要翻译：本发明涉及用于口服施用式（I）的治疗性化合物的药物组合物，其包含至少包含式（I）的治疗性化合物（参见下文），尤其是2-甲基-2- [4 - （3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢 - 咪唑并[4,5-c]喹啉-1-基） - 苯基] - 丙腈或8-（6-甲氧基 - 吡啶-3-基）-3-甲基-1-（4-哌嗪-1-基-3-三氟甲基 - 苯基）-1,3-二氢 - 咪唑并[4,5-c]喹啉-2-酮，或其互变异构体，或其药学上可接受的盐或水合物或溶剂化物; 至少一种非离子表面活性剂，其量为组合物重量的约15至约80％的量的维生素E-TPGS; 和至少一种选自聚乙二醇，聚环氧乙烷和前述的任意组合的溶解增强剂。本发明还涉及制造这种药物组合物的方法; 包含此类药物组合物和说明书的试剂盒提供了可以立即在食物消耗后约三十分钟服用药物组合物; 以及相关的用途和治疗方法。

2. 发明专利

MA34806B1 COMPOSITIONS PHARMACEUTIQUES 未知
公开(公告)号：MA34806B1
公开(公告)日：2014-01-02
申请号：MA35945
申请日：2013-05-31
申请人： NOVARTIS AG
发明人： CAO YU , HACKL WOLFGANG , LI PING , LI SHOUFENG , MIRZA TAHSEEN , ZEHENDER HARTMUT , ZHU JIAHAO
IPC分类号： A61K9/16 , A61P35/00
摘要： La présente invention concerne une composition pharmaceutique pour l'administration orale d'un composé thérapeutique de formule (I), qui comprend les éléments suivants : des granules comportant au moins un composé thérapeutique de formule (I) (voir ci-dessous), en particulier 2-méthyl-2-[4-(3-méthyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phényl]

3. 发明专利

ECSP13012654A COMPOSICIONES FARMACÉUTICAS 未知
公开(公告)号：ECSP13012654A
公开(公告)日：2013-08-30
申请号：ECSP13012654
申请日：2013-06-03
申请人： NOVARTIS AG
发明人： LI PING , CAO YU , ZHU JIAHAO , LI SHOUFENG , HACKL WOLFGANG , MIRZA TAHSEEN , ZEHENDER HARTMUT
IPC分类号： A61K9/16 , A61P35/00
摘要： La presente invención se refiere a una composición farmacéutica para la administración oral de un compuesto terapéutico de la fórmula (I), la cual comprende gránulos que comprenden por lo menos compuesto terapéutico de la fórmula (I) (véase más adelante), en particular el 2-metil-2-[4-(3-metil-2-oxo-8- quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo o la 8-(6-metoxi-piridin-3-il)-3-metil-1-(4-piperazin-1-il-3-trifluoro-metil-fenil)-1,3-dihidro-imidazo-[4,5-c]-quinolin-2-ona, o un tautómero de los mismos, o una sal farmacéuticamente aceptable, o un hidrato o un solvato de los mismos; por lo menos un tensoactivo no iónico que es la Vitamina E-TPGS, en una cantidad en el intervalo de aproximadamente el 15 a aproximadamente el 80 por ciento en peso de la composición; y por lo menos un agente mejorador de disolución seleccionado a partir de polietilenglicol, poli-óxido de etileno, y cualquier combinación de los anteriores. La presente invención también se refiere a procesos para la elaboración de estas composiciones farmacéuticas; a un kit que comprende esta composición farmacéutica y las instrucciones que disponen que la composición farmacéutica se pueda tomar desde inmediatamente hasta aproximadamente treinta minutos después del consumo de alimento; y a los usos y métodos de tratamiento relacionados.

4. 发明专利

SG190210A1 PHARMACEUTICAL COMPOSITIONS 未知
公开(公告)号：SG190210A1
公开(公告)日：2013-06-28
申请号：SG2013035480
申请日：2011-12-01
申请人： NOVARTIS AG
发明人： CAO YU , HACKL WOLFGANG , LI PING , LI SHOUFENG , MIRZA TAHSEEN , ZEHENDER HARTMUT , ZHU JIAHAO
摘要： The present invention relates to a pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), which comprises granules that comprise at least therapeutic compound of formula (I) (see below), particularly 2-Methyl-2-[4-(3-methyl-2-oxo-8- quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile or 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition; and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing. The present invention also relates to processes for making such pharmaceutical compositions; a kit comprising such pharmaceutical composition and the instructions provide that the pharmaceutical composition may be taken immediately to about thirty minutes after the consumption of food; and related uses and methods of treatment.

5. 发明专利

NZ610467A Pharmaceutical compositions of imidazoquinoline derivative compounds 未知
公开(公告)号：NZ610467A
公开(公告)日：2015-01-30
申请号：NZ61046711
申请日：2011-12-01
申请人： NOVARTIS AG
发明人： CAO YU , HACKL WOLFGANG , LI PING , LI SHOUFENG , MIRZA TAHSEEN , ZEHENDER HARTMUT , ZHU JIAHAO
IPC分类号： A61K9/16 , A61K31/4353 , A61P35/00 , C07D471/04
摘要： Provided is an oral pharmaceutical composition comprising an imidazoquinoline derivative compound of the general formula (I), wherein the variables are defined in the specification, Vitamin E TPGS and polyethylene glycol or polyethylene oxide. A preferred compound in the composition is 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile or 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one. Further provided are processes for making the compositions, a kit comprising the composition and instructions for its use and related uses of the compositions. The compositions are useful in the treatment of cancer.

6. 发明专利

PE20140792A1 COMPOSICIONES FARMACEUTICAS 未知
公开(公告)号：PE20140792A1
公开(公告)日：2014-07-09
申请号：PE2013001327
申请日：2011-12-01
申请人： NOVARTIS AG
发明人： CAO YU , HACKL WOLFGANG , LI PING , LI SHOUFENG , MIRZA TAHSEEN , ZEHENDER HARTMUT , ZHU JIAHAO
IPC分类号： A61K9/16 , A61P35/00
摘要： REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN COMPUESTO DE FORMULA (I), DONDE R1 ES NAFTILO, FENILO, ENTRE OTROS; R2 ES O O S; R3 ES ALQUILO C1-C7; R4 ES PIRIDILO, HALOGENO, CIANO, ENTRE OTROS; R5 ES H O HALOGENO; n ES 0 O 1; R6 ES OXIDO; R7 ES H O AMINO, b) UN TENSOACTIVO NO IONICO QUE ES LA VITAMINA E TPGS EN UNA CANTIDAD DE 15% A 80% EN PESO DE LA COMPOSICION, c) UN AGENTE MEJORADOR DE DISOLUCION SELECCIONADO DE POLIETILENGLICOL, POLI-OXIDO DE ETILENO Y COMBINACIONES DE LOS MISMOS. ES COMPUESTO PREFERIDO DE FORMULA (I) EL 2-METIL-2-[4-(3-METIL-2-OXO-8-QUINOLIN-3-IL-2,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-1-IL)-FENIL]-PROPIONITRILO O SU SAL DE MONOSILATO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS

7. 发明专利

CA2817618A1 PHARMACEUTICAL COMPOSITIONS 未知
公开(公告)号：CA2817618A1
公开(公告)日：2012-06-07
申请号：CA2817618
申请日：2011-12-01
申请人： NOVARTIS AG
发明人： CAO YU , HACKL WOLFGANG , LI PING , LI SHOUFENG , MIRZA TAHSEEN , ZEHENDER HARTMUT , ZHU JIAHAO
IPC分类号： A61K9/16 , A61P35/00
摘要： The present invention relates to a pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), which comprises granules that comprise at least therapeutic compound of formula (I) (see below), particularly 2-Methyl-2-[4-(3-methyl-2-oxo-8- quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile or 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition; and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing. The present invention also relates to processes for making such pharmaceutical compositions; a kit comprising such pharmaceutical composition and the instructions provide that the pharmaceutical composition may be taken immediately to about thirty minutes after the consumption of food; and related uses and methods of treatment.

8. 发明专利

PE07922014A1 COMPOSICIONES FARMACEUTICAS 未知
公开(公告)号：PE07922014A1
公开(公告)日：2014-07-09
申请号：PE0013272013
申请日：2011-12-01
申请人： NOVARTIS AG
发明人： CAO YU , HACKL WOLFGANG , LI PING , LI SHOUFENG , MIRZA TAHSEEN , ZEHENDER HARTMUT , ZHU JIAHAO
IPC分类号： A61K9/16 , A61P35/00
CPC分类号： C07D471/04 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1694 , A61K31/00
摘要： REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) UN COMPUESTO DE FORMULA (I), DONDE R1 ES NAFTILO, FENILO, ENTRE OTROS; R2 ES O O S; R3 ES ALQUILO C1-C7; R4 ES PIRIDILO, HALOGENO, CIANO, ENTRE OTROS; R5 ES H O HALOGENO; n ES 0 O 1; R6 ES OXIDO; R7 ES H O AMINO, b) UN TENSOACTIVO NO IONICO QUE ES LA VITAMINA E TPGS EN UNA CANTIDAD DE 15% A 80% EN PESO DE LA COMPOSICION, c) UN AGENTE MEJORADOR DE DISOLUCION SELECCIONADO DE POLIETILENGLICOL, POLI-OXIDO DE ETILENO Y COMBINACIONES DE LOS MISMOS. ES COMPUESTO PREFERIDO DE FORMULA (I) EL 2-METIL-2-[4-(3-METIL-2-OXO-8-QUINOLIN-3-IL-2,3-DIHIDRO-IMIDAZO-[4,5-c]-QUINOLIN-1-IL)-FENIL]-PROPIONITRILO O SU SAL DE MONOSILATO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS

9. 发明专利

ZA201303223B PHARMACEUTICAL COMPOSITIONS 未知
公开(公告)号：ZA201303223B
公开(公告)日：2014-01-29
申请号：ZA201303223
申请日：2013-05-03
申请人： NOVARTIS AG
发明人： CAO YU , HACKL WOLFGANG , LI PING , LI SHOUFENG , MIRZA TAHSEEN , ZEHENDER HARTMUT , ZHU JIAHAO
IPC分类号： A61K20060101 , A61P20060101
摘要： A pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), comprising granules that comprise at least therapeutic compound of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof; at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition; and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing; processes for making such pharmaceutical compositions; a kit comprising such pharmaceutical composition and the instructions for administration thereof; and related uses and methods of treatment.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式